We are live on
!
Find out more
Boston Trust Walden Portfolio holdings
AUM
$13.1B
Turnover
6.42%
1-Year Est. Return
24.63%
This Fund
S&P 500
This Quarter
Est. Return
+7.94%
1 Year Est. Return
+24.63%
3 Year Est. Return
+61.41%
5 Year Est. Return
+82.17%
10 Year Est. Return
+348.29%
AUM
$6.82B
AUM Growth
+$400M
(+6.2%)
Cap. Flow
-$64.1M
Cap. Flow
% of AUM
-0.94%
Top 10 Holdings %
Top 10 Hldgs %
17.87%
Holding
394
New
21
Increased
124
Reduced
197
Closed
10
Avg Time Held
3.1
years
Top 10 Avg Time Held
1.6
years
Top 20 Avg Time Held
2.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$14.8M |
| 2 |
Henry Schein
HSIC
|
+$14.3M |
| 3 |
Honeywell
HON
|
+$14.2M |
| 4 |
Pediatrix Medical
MD
|
+$13.5M |
| 5 |
Charles River Laboratories
CRL
|
+$13.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BCR
CR Bard Inc.
BCR
|
+$62.1M |
| 2 |
CVS Health
CVS
|
+$18M |
| 3 |
Accendra Health
ACH
|
+$14.8M |
| 4 |
Ubiquiti
UI
|
+$13.1M |
| 5 |
Eagle Bancorp
EGBN
|
+$11.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 19.91% |
| 2 | Healthcare | 16.24% |
| 3 | Technology | 15.4% |
| 4 | Industrials | 13.98% |
| 5 | Consumer Discretionary | 8.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
Landstar System
LSTR
$5.85B
| $21.6M | 0.32% |
207,370
+27,714
| +15% | +$2.78M |
2016 Q1
7 quarters
|
|
102
Sysco
SYY
$40.4B
| $21.5M | 0.31% |
353,538
-24,790
| -7% | -$1.4M |
2013 Q2
18 quarters
|
|
|
VAR
103
DELISTED
Varian Medical Systems, Inc.
VAR
| $21.5M | 0.31% |
193,091
-1,915
| -1% | -$206K |
2013 Q2
18 quarters
|
|
104
InterDigital
IDCC
$8.47B
| $20.9M | 0.31% |
274,963
-7,961
| -3% | -$595K |
2013 Q2
18 quarters
|
|
105
CubeSmart
CUBE
$8.68B
| $20.6M | 0.3% |
713,311
+145,853
| +26% | +$4.07M |
2017 Q3
1 quarter
|
|
106
The Marzetti Company
MZTI
$2.82B
| $20.5M | 0.3% |
158,943
+24,594
| +18% | +$3.1M |
2017 Q3
1 quarter
|
|
107
US Physical Therapy
USPH
$1.28B
| $20.3M | 0.3% |
280,557
+1,952
| +0.7% | +$133K |
2015 Q2
10 quarters
|
|
108
Innovex International
INVX
$1.92B
| $20M | 0.29% |
419,248
+120,858
| +41% | +$5.4M |
2014 Q4
12 quarters
|
|
|
HRC
109
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $19.8M | 0.29% |
235,490
-4,274
| -2% | -$346K |
2017 Q1
3 quarters
|
|
110
Marsh
MRSH
$89B
| $19.5M | 0.29% |
239,555
+32,770
| +16% | +$2.72M |
2013 Q2
18 quarters
|
|
111
Chevron
CVX
$430B
| $19.5M | 0.29% |
155,404
+16,077
| +12% | +$1.91M |
2013 Q2
18 quarters
|
|
112
Booking.com
BKNG
$125B
| $19.3M | 0.28% |
277,075
+5,825
| +2% | +$422K |
2016 Q4
4 quarters
|
|
|
113
Pediatrix Medical
MD
$2.26B
| $19.2M | 0.28% |
359,011
+285,955
| +391% | +$13.5M |
2013 Q2
18 quarters
|
|
114
Bio-Techne
TECH
$11.4B
| $18.9M | 0.28% |
582,120
-11,452
| -2% | -$364K |
2013 Q2
18 quarters
|
|
115
McDonald's
MCD
$172B
| $18.7M | 0.27% |
108,520
-2,192
| -2% | -$368K |
2013 Q2
18 quarters
|
|
116
Texas Capital Bancshares
TCBI
$3.94B
| $18.6M | 0.27% |
209,107
-2,521
| -1% | -$218K |
2013 Q2
18 quarters
|
|
|
LHO
117
DELISTED
LaSalle Hotel Properties
LHO
| $17.8M | 0.26% |
633,952
-16,177
| -2% | -$464K |
2016 Q1
7 quarters
|
|
118
TE Connectivity
TEL
$61.7B
| $17.6M | 0.26% |
185,230
+125,560
| +210% | +$11.6M |
2016 Q1
7 quarters
|
|
119
Power Integrations
POWI
$2.51B
| $17.4M | 0.26% |
473,680
+17,062
| +4% | +$651K |
2013 Q2
18 quarters
|
|
120
MillerKnoll
MLKN
$1.49B
| $17.3M | 0.25% |
433,071
-10,116
| -2% | -$355K |
2013 Q2
18 quarters
|
|
|
EGOV
121
DELISTED
NIC Inc
EGOV
| $17.3M | 0.25% |
1,044,009
-60,800
| -6% | -$1.03M |
2015 Q3
9 quarters
|
|
122
CVB Financial
CVBF
$3.84B
| $17.1M | 0.25% |
727,079
-20,322
| -3% | -$483K |
2016 Q1
7 quarters
|
|
123
DELISTED
Comerica
CMA
| $17M | 0.25% |
196,099
-220
| -0.1% | -$17.7K |
2013 Q2
18 quarters
|
|
124
Tanger
SKT
$4.06B
| $17M | 0.25% |
641,453
-48,787
| -7% | -$1.21M |
2014 Q4
12 quarters
|
|
|
POLY
125
DELISTED
Plantronics, Inc.
POLY
| $16.9M | 0.25% |
335,945
-107,398
| -24% | -$5.28M |
2013 Q2
18 quarters
|
|
Similar funds
Boston Trust Walden's Q4 2017 Portfolio in Review
As of Q4 2017, Boston Trust Walden held 394 positions worth $6.82B, up 6.2% from $6.42B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Boston Trust Walden's Q4 2017 filing shows 21 new, 124 increased, 197 reduced and 10 closed positions. Its largest new stake was Charles River Laboratories: 122,536 shares worth $13.4M. The largest sale was CR Bard Inc., an estimated $62.1M.
By sector, the portfolio is most concentrated in Financials at 20% of assets, down from 20% a quarter earlier, followed by Healthcare and Technology.
- Boston Trust Walden's largest Q4 2017 buy was Charles River Laboratories: 122,536 shares worth $13.4M.
- Boston Trust Walden added most to Becton Dickinson in Q4 2017, an estimated $14.8M increase.
- Boston Trust Walden's biggest Q4 2017 reduction was CVS Health, cutting an estimated $18M.
- Boston Trust Walden fully exited CR Bard Inc. in Q4 2017, selling an estimated $62.1M.
- Boston Trust Walden's ten largest holdings make up 18% of its $6.82B portfolio in Q4 2017.
- Boston Trust Walden opened 21 new positions and closed 10 in Q4 2017.
- Boston Trust Walden's portfolio value rose 6.2% quarter-over-quarter to $6.82B.
Based on Boston Trust Walden's 13F filing for Q4 2017, filed 29 Jan 2018.